We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

40 hedge funds and large institutions have $32.1M invested in Bolt Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.23% more ownership

Funds ownership: 3.08% → 3.31% (+0.23%)

0% more funds holding

Funds holding: 40 → 40 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1% less capital invested

Capital invested by funds: $32.4M → $32.1M (-$321K)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

Holders
40
Holders Change
–
Holders Change %
0%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
8
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$2.71M
2
AI
Acuitas Investments
Washington
+$731K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$277K
4
Citadel Advisors
Citadel Advisors
Florida
+$234K
5
Squarepoint
Squarepoint
New York
+$102K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$433K
2
Millennium Management
Millennium Management
New York
-$209K
3
VCIM
Velan Capital Investment Management
Georgia
-$195K
4
NM
Newtyn Management
New York
-$183K
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$107K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$4.96M – – –
TCM
2
Tang Capital Management
California
$4.27M +$2.71M +85,312 +105%
Citadel Advisors
3
Citadel Advisors
Florida
$3.82M +$234K +7,385 +5%
SI
4
Sofinnova Investments
California
$3.53M – – –
PBPIA
5
Pivotal bioVenture Partners Investment Advisor
California
$2.42M – – –
O
6
OrbiMed
New York
$1.97M – – –
NFGH
7
Nan Fung Group Holdings
Hong Kong
$1.49M – – –
SB
8
Samsara BioCapital
California
$1.34M – – –
NM
9
Newtyn Management
New York
$1.28M -$183K -5,756 -10%
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.19M – – –
BOTOTLSJU
11
Board of Trustees of The Leland Stanford Junior University
California
$921K – – –
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$640K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$619K +$43.2K +1,360 +6%
AI
14
Acuitas Investments
Washington
$589K +$731K +23,019 New
HCM
15
Hawkeye Capital Management
Florida
$531K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$451K +$277K +8,711 +98%
BlackRock
17
BlackRock
New York
$369K +$21.4K +673 +5%
Goldman Sachs
18
Goldman Sachs
New York
$364K +$1.75K +55 +0.4%
Assenagon Asset Management
19
Assenagon Asset Management
Luxembourg
$203K -$107K -3,377 -30%
JP Morgan Chase
20
JP Morgan Chase
New York
$165K -$96.3K -3,033 -32%
PFMU
21
Privium Fund Management (UK)
United Kingdom
$148K – – –
Millennium Management
22
Millennium Management
New York
$146K -$209K -6,572 -54%
BCM
23
Bridgeway Capital Management
Texas
$130K +$41.3K +1,300 +35%
MAM
24
Marquette Asset Management
Minnesota
$125K – – –
Fidelity Investments
25
Fidelity Investments
Massachusetts
$101K +$1.21K +38 +1%
1
2

BOLT Hedge Fund Activity: Q2 2023 in Review

40 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2023, worth a combined $32.1M — down 0.99% from $32.4M a quarter earlier.

Fund positioning in BOLT was balanced in Q2 2023: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 9 trimmed.

The largest buyer was Tang Capital Management, adding an estimated $2.71M. The largest seller was Morgan Stanley, cutting an estimated $433K.

  • 40 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $32.1M of Bolt Biotherapeutics stock for Q2 2023, down 0.99% quarter-over-quarter.
  • 4 funds opened new Bolt Biotherapeutics positions in Q2 2023 and 4 closed out, a net change of 0 holders.
  • The largest Bolt Biotherapeutics buyer in Q2 2023 was Tang Capital Management, an estimated $2.71M added.
  • The largest Bolt Biotherapeutics seller in Q2 2023 was Morgan Stanley, an estimated $433K sold.

Based on aggregated 13F filings for Q2 2023.